The Weekly Summary

(From L to R) Brunei Sultan Hassanal Bolkiah, Russian President Vladimir Putin, Chinese President Xi Jinping, his wife Peng Liyuan, U.S. President Barack Obama walk before the ceremonial reception held for members of the APEC Economic Leaders' Meeting by Chinese President Xi Jinping and Peng Liyuan in Beijing on November 10, 2014. Top leaders and ministers of the 21-member APEC group are meeting in Beijing from November 7 to 11. AFP PHOTO / POOL / MICHAEL KLIMENTYEVMichael Klimentyev/AFP/Getty Images

November 10th – November 16th

In the general news, the U.S and China reached breakthrough agreement to curb greenhouse emissions. In Europe, Russia flagrantly invaded Ukraine with legions of tanks. In the U.S., the second round of enrollment for Obamacare was met with downgraded expectations from the White House.

In healthcare business news, Dendreon (DNDN) threw in the towel filing for bankruptcy.

On the data front, Achillion (ACHN) stock was up 28% when data supported their drug ACH-3102 when combined with Gilead’s (GILD) Sovaldi. Meanwhile, GILD’s Harvoni worked well in treatment failure HCV, and Abbvie’s (ABBV) Hep C drug Enanta worked in genotype 4 patients. In rheumatology, Amgen’s (AMGN) psoriasis drug brodalumab beat JNJ’s Stelara.

From the FDA, Sanofi’s MS drug Lemtrada was finally approved. In other regulatory news, CMS announced plans to cover CT-scan lung cancer screening.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.